Discovery Laboratories: Clinical Trial Data over Next Year Could Validate the Promise of Aerosurf (DSCO, Buy, $1.60)Investment Overview The Stock Market Has Written off Aerosurf The current stock market valuation for Discovery Laboratories of $13 million (8 million… Discovery Laboratories: New CEO and Update on Aerosurf (DSCO, $2.26)Upcoming Key Events There are two very important events in the next year. The first is reporting of results in a… Discovery Laboratories: Results for Aerosurf in Phase 2a Trial are Encouraging; Why Then Did the Stock Crash? (DSCO, Buy, $0.30)Introduction This report discusses the results of Discovery Laboratory’s first in human, phase 2a trial of Aerosurf. In writing this report,… Discovery Laboratories: Update from the 2Q, 2015 Conference Call Provides Timelines for Important Aerosurf Phase 2 Trials (DSCO, Buy, $0.47)Key Points Phase 2 trials are enrolling rapidly. Discovery Laboratories: What I Intend to Do in the Aftermath of a Disastrous Stock Offering (DSCO, Buy, $0.54)Quick Summary Discovery Laboratories: An Analysis of Phase 2a Results for Aerosurf and What to do with the Stock (DSCO, $0.81, for paid subscribers)Glossary of Important Definitions For those of you who are not familiar with terms used in neonatology, I am starting this… Comments on Antares, Agenus, Cytokinetics, Discovery Laboratories and ZS PharmaSmithOnStocks Mailbox Discovery Laboratories: Focus is Totally on Aerosurf Development (DSCO, $1.43, Hold)Investment Thesis During the conference call on March 16, 2015 discussing 4Q, 2014 results, management announced that it had decided to… Discovery Laboratories: Delay in Completion of Aerosurf Phase 2a Trial and Continued Disappointing Sales of Surfaxin Weigh on the Stock (DSCO, $1.53, Hold)
Phase 2a Aerosurf trial completion has been pushed back to 1Q, 2015 from 4Q, 2014. Discovery Laboratories Has Formed an Important Collaboration with Battelle to Develop Aerosurf (DSCO, Buy, $1.69)
This agreement partners Discovery with a world class medical device developer and meaningfully de-risks development of Aerosurf. Discovery Laboratories: My Current Thinking on the Surfaxin Launch and Aerosurf Phase 2 Trials (DSCO, Buy/Hold, $1.62)Investment Thesis At the time of launch of Surfaxin on November 8, 2013 Discovery Laboratory’s (DSCO) stock was selling at $2.00.… Discovery Laboratories: A Look at the Surfaxin Launch and the Phase 2a Trial of Aerosurf (DSCO, Buy, $1.79, free content)Launch of Surfaxin The launch of Surfaxin has begun and initial results were below expectations causing the Company a few months… Discovery Laboratories: An Update on the Surfaxin Launch and the Phase 2 Clinical Trial Program for Aerosurf (DSCO, Buy, $1.72)Introduction and Overview This note updates recent progress of the company along with my detailed investment outlook which I break into… Thoughts on the Market Correction in Biotechnology StocksThis Has Been a Tough Correction The recent sharp market correction and rotation out of growth stocks like biotechnology and technology… San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)What SmithOnStocks Is All About Discovery Laboratories: An Asymmetric Opportunity (DSCO, $2.07)I have just published the first of a series of reports on Discovery Laboratories. Discovery Laboratories (DSCO, $2.07): An Asymmetric Opportunity Discovery Laboratories: Removal of Financing Overhang Is a Catalyst for the Stock (DSCO, $2.17)Investment Thesis Discovery Laboratories: What the Marketing Approval of Surfaxin Could Mean to the Stock (DSCO, $2.72)Surfaxin is Finally Cleared for Commercialization in the US SmithOnStocks Opines on Biotechnology Stocks, June 2, 2013Overview of This Week's Report SmithOnStocks Opines on Stocks May 19, EditionOne Approach for Investing in Emerging Biotechnology Stocks Discovery Laboratories (DSCO): An Update and Buy Re-iterationI have just published a new report on Discovery Laboratories; this emerging company has two products approved for U.S. marketing… |